氯雷他定市场 - 全球产业规模、份额、趋势、机会、预测：按等级类型、过敏原类型、测试类型、地区和竞争格局划分，2021-2031年

全球氯雷他定市场预计将从 2025 年的 1.6452 亿美元成长到 2031 年的 1.9979 亿美元，复合年增长率为 3.29%。

氯雷他定是一种选择性週边组织胺受体拮抗剂，主要用于治疗过敏性鼻炎和荨麻疹，且不会引起镇静作用。市场成长的主要驱动因素是全球过敏性疾病负担日益加重以及消费者对易于取得的非处方药的偏好不断增长。此外，城市扩张和由此导致的污染加剧也起到了催化剂的作用，推动了对有效抗组织胺药物的需求。

阻碍市场发展的主要障碍是市场饱和，因为新一代抗组织胺药物凭藉其卓越的疗效和安全性，已占据主导地位。在这种竞争环境下，庞大的患者群仍需缓解症状。根据美国气喘与过敏基金会（AAFA）预测，到2024年，美国将有约1亿人患有各种过敏症。虽然如此高的盛行率表明对氯雷他定等药物的需求仍然存在，但来自先进药物的激烈竞争，对这类药物实现市场主导地位构成了重大挑战。

市场驱动因素

气候变迁导致花粉季延长，显着推高了氯雷他定的需求，因为患者需要缓解症状的时间也随之延长。全球气温上升导致许多地区的冰冻期延长，使得植物能够更长时间、更高浓度地产生花粉。这种环境变化迫使过敏患者全年服用抗组织胺药，而不仅仅是在传统的过敏高峰期，导致销售成长。根据气候中心（Climate Central）2024年3月发布的报告《季节性过敏：花粉和霉菌》，自1970年以来，美国203个地区的冰冻期平均延长了19天。冰冻期的延长与人们持续光顾药局以及非镇静性抗组织胺消费量的增加密切相关。同时，空气品质恶化（值得注意的是，在IQAir发布的《2023年全球空气品质报告》中，只有7个国家达到了世卫组织PM2.5标准）加剧了呼吸系统疾病，进一步支撑了市场需求。

过敏性鼻炎发生率的上升是全球氯雷他定市场的主要驱动力，不断增长的患者群体需要持续的治疗性介入。由于遗传和环境因素的双重影响，过敏性鼻炎的盛行率不断上升，领先的製药公司在过敏领域实现了持续的收入成长，这支撑了对氯雷他定等成熟药物的持续需求。这种需求正变得越来越稳定，而不再只是季节性的，从而推动了主要市场参与者的强劲业绩。例如，拜耳公司于2024年3月发布的2023财年年度报告显示，经汇率和产品组合调整后，其过敏和感冒类产品的销售额增长了7.2%。这主要得益于欧洲和北美市场的强劲需求。这一成长趋势凸显了过敏管理产品在消费者保健产品系列中的关键作用，并反映出人们越来越依赖成熟的抗组织胺药物来维持日常生活品质。

市场挑战

全球氯雷他定市场面临一个重大障碍：由于新一代抗组织胺的出现，市场已趋于饱和。这些先进的药物替代疗法通常比氯雷他定具有更优的疗效和安全性，包括起效更快、镇静作用更小。这种激烈的竞争正在阻碍市场成长，因为相当一部分患者转向了这些现代治疗方法，从而侵蚀了氯雷他定的市场份额，并限制了其在处方药和非处方药领域的收入潜力。

这种竞争饱和的影响因对有效长期治疗过敏性疾病的迫切需求而进一步加剧。根据气喘与过敏基金会预测，到2024年，过敏症将成为美国第六大慢性病死因。这项高排名凸显了过敏症带来的沉重健康负担，并促使患者和医疗保健提供者积极寻求最有效、最先进的治疗方案。因此，随着慢性过敏症的普遍流行，消费者转向最新的药物创新，氯雷他定在保持其竞争优势方面面临巨大的挑战。

市场趋势

随着消费者越来越倾向于选择便利的线上平台，电子商务和数位药局分销管道的快速成长正在从根本上改变氯雷他定的供应方式。这种转变帮助慢性过敏患者利用订阅服务，确保在漫长的花粉季期间获得稳定的抗组织胺药物供应。数位货架便于大宗购买比价，增强了氯雷他定直接面向消费者的销售管道，同时也帮助主要参与者优化其数位化供应链。根据Haleon plc于2024年3月发布的2023财年年度报告，电子商务销售额增长了17%，占全球总销售额的10%，这反映出消费者在购买自我护理产品时普遍转向数位化管道。

消费者对价格日益敏感，推动了高性价比学名药市场渗透率的不断提高，这正在显着改变行业格局。零售商积极推广价格更低、疗效相当的自有品牌氯雷他定类药物，提升了非专利生产商的销售量。这一趋势正在形成一种市场环境，在这个环境中，价格承受能力而非品牌忠诚度正在影响消费者的购买行为，并迫使原厂药生产商在价格方面竞争。根据瑞迪博士实验室（Dr. Reddy's Laboratories）于2024年7月发布的2023-2024财年年度报告，全球非专利收入达到2455亿卢比，年增15%。这一成长主要得益于北美市场的强劲表现，该地区对非专利抗组织胺药物的需求依然旺盛。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球氯雷他定市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 分级（USP标准级、EP标准级、药用标准级）
  • 过敏原类型（食物、吸入物、药物、其他）
  • 依测试类型（体外测试、体外测试）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美氯雷他定市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲氯雷他定市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区氯雷他定市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：氯雷他定在中东和非洲的市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美氯雷他定市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球氯雷他定市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• R-Biopharm AG
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• GSK plc
• bioMerieux, Inc.
• Danaher Corporation
• Thermo Fisher Scientific Inc.
• Siemens Healthineers AG
• AbbVie Inc.
• Pfizer Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Loratadine Market is projected to expand from USD 164.52 Million in 2025 to USD 199.79 Million by 2031, registering a compound annual growth rate (CAGR) of 3.29%. Functioning as a selective peripheral histamine receptor antagonist, loratadine is primarily utilized for treating allergic rhinitis and urticaria without inducing sedative effects. The market's growth is fundamentally driven by the escalating global burden of allergic conditions and a rising consumer preference for readily accessible nonprescription medications. Furthermore, the expansion of urban environments and the associated increase in pollution levels act as catalysts, intensifying the demand for effective antihistamine treatments.

A significant obstacle hindering market progression is the saturation of the sector by newer generation antihistamines that boast superior efficacy and safety profiles. This competitive environment persists alongside a vast patient demographic requiring symptom relief. According to the Asthma and Allergy Foundation of America, approximately 100 million people in the United States lived with various types of allergies in 2024. While this substantial prevalence highlights the continued necessity for drugs like loratadine, the fierce competition from advanced pharmacological alternatives remains a critical barrier to achieving market dominance.

Market Driver

Prolonged pollen seasons resulting from climate change are significantly bolstering the demand for loratadine by extending the periods during which patients require symptomatic relief. As global temperatures rise, freeze-free intervals in many regions are widening, enabling plants to produce pollen for longer windows and often at higher intensities. This environmental shift compels allergy sufferers to use antihistamines for extended durations throughout the year rather than solely during traditional peak months, thereby increasing unit sales volume. According to Climate Central's March 2024 report, 'Seasonal Allergies: Pollen and Mold,' the freeze-free growing season has lengthened by an average of 19 days across 203 locations in the United States since 1970. This extension correlates with sustained pharmacy visits and consumption of non-sedating antihistamines, while worsening air quality-highlighted by IQAir's 'World Air Quality Report 2023' where only seven countries met WHO PM2.5 guidelines-synergistically aggravates respiratory conditions, broadly supporting market intake.

The increasing prevalence of allergic rhinitis serves as a foundational driver for the Global Loratadine Market, necessitating consistent therapeutic intervention for a growing patient base. As incidence rates climb due to both genetic and environmental factors, major pharmaceutical manufacturers are recording sustained revenue growth in their allergy segments, validating the ongoing need for proven molecules like loratadine. This demand is not merely seasonal but increasingly perennial, driving robust performance for key market players. For instance, Bayer AG's 'Annual Report 2023', released in March 2024, reported a 7.2 percent increase in sales within the Allergy & Cold category on a currency- and portfolio-adjusted basis, driven largely by high demand in Europe and North America. This upward trend underscores the critical role of allergy management products in consumer healthcare portfolios and reflects the expanding reliance on established antihistamine treatments to manage daily quality of life.

Market Challenge

The Global Loratadine Market faces a formidable obstacle due to the saturation of the sector by newer generation antihistamines. These advanced pharmacological alternatives often present superior efficacy and safety profiles, such as a faster onset of action and reduced sedative effects compared to loratadine. This intense competition hampers market growth by diverting a significant portion of the patient population toward these modern therapies, thereby eroding loratadine's market share and limiting its revenue potential in both prescription and over-the-counter segments.

The impact of this competitive saturation is magnified by the critical need for effective long-term management of allergic conditions. According to the Asthma and Allergy Foundation of America, in 2024, allergies ranked as the sixth leading cause of chronic illness in the United States. This high ranking underscores the severity of the health burden, compelling patients and healthcare providers to aggressively seek out the most potent and advanced treatment options available. Consequently, loratadine faces significant headwinds in retaining its dominance as the widespread prevalence of chronic allergies drives consumers toward the latest pharmacological innovations.

Market Trends

The rapid growth of e-commerce and digital pharmacy distribution channels is fundamentally reshaping loratadine accessibility, as consumers increasingly prefer online platforms for convenience. This shift supports chronic allergy sufferers who utilize subscription services to ensure steady antihistamine supplies during extended pollen seasons. Digital shelves facilitate bulk-pack comparisons, strengthening the molecule's direct-to-consumer presence while allowing major players to optimize digital supply chains. According to Haleon plc's 'Annual Report 2023' from March 2024, e-commerce sales grew by 17 percent to account for 10 percent of total global sales, reflecting the widespread migration toward digital procurement for self-care products.

The rising market penetration of cost-effective generic alternatives is significantly altering the sector, driven by heightened consumer price sensitivity. Retailers are aggressively promoting private-label loratadine that offers identical therapeutic benefits at reduced costs, thereby fueling volume growth for generic manufacturers. This trend creates a market environment where affordability dictates consumption patterns over brand loyalty, pressuring original formulators to compete on value. According to Dr. Reddy's Laboratories' 'Annual Report 2023-24' released in July 2024, revenue from the Global Generics segment reached Rs. 245.5 billion, a 15 percent growth largely driven by strong performance in North America where generic antihistamine uptake remains robust.

Key Market Players

• R-Biopharm AG
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• GSK plc
• bioMerieux, Inc.
• Danaher Corporation
• Thermo Fisher Scientific Inc.
• Siemens Healthineers AG
• AbbVie Inc.
• Pfizer Inc.

Report Scope

In this report, the Global Loratadine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Loratadine Market, By Grade Type

• USP Standard Grade
• EP Standard Grade
• Medicine Standard Grade

Loratadine Market, By Allergen Type

• Food
• Inhaled
• Drug
• Others

Loratadine Market, By Test Type

• In-vivo test
• In-vitro test

Loratadine Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Loratadine Market.

Available Customizations:

Global Loratadine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Loratadine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Grade Type (USP Standard Grade, EP Standard Grade, Medicine Standard Grade)
  • 5.2.2. By Allergen Type (Food, Inhaled, Drug, Others)
  • 5.2.3. By Test Type (In-vivo test, In-vitro test)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Loratadine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Grade Type
  • 6.2.2. By Allergen Type
  • 6.2.3. By Test Type
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Loratadine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Grade Type
      • 6.3.1.2.2. By Allergen Type
      • 6.3.1.2.3. By Test Type
  • 6.3.2. Canada Loratadine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Grade Type
      • 6.3.2.2.2. By Allergen Type
      • 6.3.2.2.3. By Test Type
  • 6.3.3. Mexico Loratadine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Grade Type
      • 6.3.3.2.2. By Allergen Type
      • 6.3.3.2.3. By Test Type

7. Europe Loratadine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Grade Type
  • 7.2.2. By Allergen Type
  • 7.2.3. By Test Type
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Loratadine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Grade Type
      • 7.3.1.2.2. By Allergen Type
      • 7.3.1.2.3. By Test Type
  • 7.3.2. France Loratadine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Grade Type
      • 7.3.2.2.2. By Allergen Type
      • 7.3.2.2.3. By Test Type
  • 7.3.3. United Kingdom Loratadine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Grade Type
      • 7.3.3.2.2. By Allergen Type
      • 7.3.3.2.3. By Test Type
  • 7.3.4. Italy Loratadine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Grade Type
      • 7.3.4.2.2. By Allergen Type
      • 7.3.4.2.3. By Test Type
  • 7.3.5. Spain Loratadine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Grade Type
      • 7.3.5.2.2. By Allergen Type
      • 7.3.5.2.3. By Test Type

8. Asia Pacific Loratadine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Grade Type
  • 8.2.2. By Allergen Type
  • 8.2.3. By Test Type
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Loratadine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Grade Type
      • 8.3.1.2.2. By Allergen Type
      • 8.3.1.2.3. By Test Type
  • 8.3.2. India Loratadine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Grade Type
      • 8.3.2.2.2. By Allergen Type
      • 8.3.2.2.3. By Test Type
  • 8.3.3. Japan Loratadine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Grade Type
      • 8.3.3.2.2. By Allergen Type
      • 8.3.3.2.3. By Test Type
  • 8.3.4. South Korea Loratadine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Grade Type
      • 8.3.4.2.2. By Allergen Type
      • 8.3.4.2.3. By Test Type
  • 8.3.5. Australia Loratadine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Grade Type
      • 8.3.5.2.2. By Allergen Type
      • 8.3.5.2.3. By Test Type

9. Middle East & Africa Loratadine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Grade Type
  • 9.2.2. By Allergen Type
  • 9.2.3. By Test Type
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Loratadine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Grade Type
      • 9.3.1.2.2. By Allergen Type
      • 9.3.1.2.3. By Test Type
  • 9.3.2. UAE Loratadine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Grade Type
      • 9.3.2.2.2. By Allergen Type
      • 9.3.2.2.3. By Test Type
  • 9.3.3. South Africa Loratadine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Grade Type
      • 9.3.3.2.2. By Allergen Type
      • 9.3.3.2.3. By Test Type

10. South America Loratadine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Grade Type
  • 10.2.2. By Allergen Type
  • 10.2.3. By Test Type
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Loratadine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Grade Type
      • 10.3.1.2.2. By Allergen Type
      • 10.3.1.2.3. By Test Type
  • 10.3.2. Colombia Loratadine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Grade Type
      • 10.3.2.2.2. By Allergen Type
      • 10.3.2.2.3. By Test Type
  • 10.3.3. Argentina Loratadine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Grade Type
      • 10.3.3.2.2. By Allergen Type
      • 10.3.3.2.3. By Test Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Loratadine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. R-Biopharm AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Teva Pharmaceutical Industries Ltd.
• 15.3. Sun Pharmaceutical Industries Ltd.
• 15.4. GSK plc
• 15.5. bioMerieux, Inc.
• 15.6. Danaher Corporation
• 15.7. Thermo Fisher Scientific Inc.
• 15.8. Siemens Healthineers AG
• 15.9. AbbVie Inc.
• 15.10. Pfizer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer